PharmaVoice

JULY 28, 2025

Ivonescimab, which was developed by China-based Akeso and licensed to Summit Therapeutics, targets both PD-1 and vascular endothelial growth factor (VEGF), a protein that promotes blood vessel growth and shields tumors from the immune system. This will help answer the bigger question: Can it replace Keytruda?” Smith said.

Immunization

Drug Topics

JUNE 13, 2025

billion people used social media in 2021, and this number is likely to grow to almost 6 billion in 2027. Social media browsing is the most popular online activity,” wrote authors of the study. According to the statistics, [over] 4.26 In April 2023, a total of 4.8 billion people, or 59.9% of the world’s population, were social media users.”

Specialty Pharmacies

PharmaShots

JULY 23, 2025

Given the prevalence of DLL3 overexpression across a variety of neuroendocrine tumors, at Zai we are continuing to advance a clear strategy to expand the reach of ZL-1310 across multiple high-need DLL3-expressing solid tumor types, with our first regulatory submission targeted in 2027. mg/kg, 1.2 mg/kg, 1.6 mg/kg, 2.0 mg/kg, 2.4

Chemotherapy

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.

Mayo Clinic

European Pharmaceutical Review

MAY 4, 2023

According to Research and Markets 8 , the market for bispecific antibodies for cancer is forecasted to grow by $400 million during 2022-2027, due to the increasing prevalence of cancer worldwide. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity.

Immunization

pharmaphorum

JANUARY 17, 2023

Its vocal biomarkers are already being used to gauge the effect of drug treatments for dementia, including in the phase 2 TAURIEL trial of Roche/AC Immune’s’s tau protein-targeted antibody semorinemab. million) to its top-line in 2023 with “considerable growth” next year.

Immunization

The Checkup by Singlecare

NOVEMBER 6, 2023

According to the FDA announcement, the most serious side effect of Wezlana is infection because the prescription affects your immune response. Crohn’s disease What are the possible side effects of Wezlana?

FDA

Roots Analysis

OCTOBER 4, 2023

They are designed to recognize and bind to two specific molecules, such as a tumor cell and an immune cell, or two different parts of the same molecule. Bispecific antibodies are a type of antibody that can bind to two different targets at the same time. during the period 2023-2035. during the period 2023-2035.

Chemotherapy

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027.

Immunization

pharmaphorum

NOVEMBER 18, 2022

” T1D occurs when the immune system attacks and destroys the insulin-producing pancreatic beta cells that make insulin, and occurs in three stages. In stage 1 there are antibodies against the beta calls, but blood glucose levels remain normal and there are no symptoms.

FDA

European Pharmaceutical Review

MARCH 7, 2024

billion between 2022 to 2027. Firstly, alpha particles exhibit greater biological effectiveness by inducing irreparable DNA double-strand breaks, minimising the risk of resistance or immune escape in tumour cells. However, by employing alpha particles, TAT offers two crucial advantages.

Pharmaceutical Companies

Pharmaceutical Technology

JUNE 21, 2023

With this pipeline, Empress hopes to address unmet clinical needs in immune and inflammatory conditions, and metabolic, neurologic, oncologic, and pain disorders. Analysts forecast the biologics market to be worth $120 billion more than small molecules by 2027. Murray KcKinnon, PhD He joined Empress as chief scientific officer.

Compounding

Pharmaceutical Technology

APRIL 24, 2023

With early nanoparticle studies, researchers often found the human body’s innate immune response to drugs and the short-lasting effects of drugs challenging, as they can also reduce a drug’s efficacy. GlobalData predicts that Comirnaty’s sales will increase by more than 20% between 2024 and 2027.

Vaccines

Blog: Ask a Student Pharmacist

JUNE 21, 2023

Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. J Chromatogr B Analyt Technol Biomed Life Sci.

Compounding

pharmaphorum

JANUARY 10, 2023

Other IgG proteases are being developed to tackle the issue of pre-existing immunity against AAV, but according to Selecta chief executive Carsten Brun these tend to be derived from common human pathogens – which means they themselves can be the target of existing antibodies.

Immunization

Pharmaceutical Technology

APRIL 24, 2023

. “Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

Vaccines

European Pharmaceutical Review

MARCH 4, 2024

percent through 2027. Barriers that complicate biologics delivery include their susceptibility to enzyme degradation, serum protein interactions, electrostatic repulsion, neutralising immune reaction, and intracellular shielding like endosomal escape, among others.

FDA

ISPE

MARCH 8, 2023

In the remaining 17 studies, many contaminants were potent prescription-only medications such as antihypertensive drugs including hydrochlorothiazide, olmesartan, and enalapril; anticancer drugs including vincristine; and immune-modulating drugs such as azathioprine.

Compounding

BuzzRx

AUGUST 30, 2022

In 2018-2019, 25 states did not cover all the vaccines recommended by the Advisory Committee on Immunization Practices (ACIP). The Trump Administration’s drug rebate rule will be delayed until 2032 The Inflation Reduction Act includes a provision to delay the implementation of the Trump administration’s drug rebate rule from 2027 to 2032.

Vaccines